Counselors in South Charleston, WV Accepting Medicare

25 Counselors found. Showing 21 - 25

Josephine Marie Hensley, MA, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 90 Maccorkle Ave Sw Ste 201, South Charleston, WV 25303 Phone: 304-941-6256    Fax: 304-533-0379

Ms. Stacy Marie Gooden, M.A. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 218 D St, South Charleston, WV 25303 Phone: 304-720-3835

Mr. Randall Alan Clifford, LPC, LCSW Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 4501 Maccorkle Ave Sw, Ste 103, South Charleston, WV 25309 Phone: 304-768-1401    Fax: 304-768-1402

Lindsay Adkins Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1009 Ridge Dr, South Charleston, WV 25309 Phone: 304-932-9250

Ann Mueller Flynt, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1113b Jefferson Rd, South Charleston, WV 25309 Phone: 304-993-3727

News Archive

Study looks at transpalatal advancement pharyngoplasty procedure for sleep apnea

Treatment with surgery or an oral appliance that adjusts the jaw is associated with improvements in obstructive sleep apnea, a condition caused by blocked upper airways in which patients periodically stop breathing during sleep, according to two reports in the May issue of Archives of Otolaryngology–Head & Neck Surgery.

Discovery holds promise in fighting cancer, AIDS and autoimmune disorders

Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders.

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.

Active management boosts patient satisfaction with COPD care

A disease management program for chronic obstructive pulmonary disease based on the Chronic Care Model leads to greater patient satisfaction with care than standard disease management, a randomized trial suggests.

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

Read more Medical News

› Verified 7 days ago

• 1
• 2(current)